2024 Q2 Form 10-Q Financial Statement

#000148500324000009 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $9.200M $3.400M
YoY Change 155.56% 4.84%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.560M $5.445M
YoY Change -7.49% -43.1%
% of Gross Profit
Research & Development $15.31M $17.46M
YoY Change -17.34% 4.93%
% of Gross Profit
Depreciation & Amortization $255.0K $1.693M
YoY Change -64.08% 138.45%
% of Gross Profit
Operating Expenses $20.87M $22.91M
YoY Change -14.92% -12.62%
Operating Profit -$11.67M -$19.51M
YoY Change -44.34% -15.07%
Interest Expense $508.0K $532.0K
YoY Change -56.84% -136.02%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$11.16M -$18.98M
YoY Change -43.6% -22.63%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$11.16M -$18.98M
YoY Change -43.84% -22.99%
Net Earnings / Revenue -121.33% -558.18%
Basic Earnings Per Share -$0.27 -$0.46
Diluted Earnings Per Share -$0.27 -$0.46
COMMON SHARES
Basic Shares Outstanding 41.54M shares 41.54M shares
Diluted Shares Outstanding 41.54M shares 40.94M shares

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $40.36M $56.52M
YoY Change -65.53% -59.34%
Cash & Equivalents $40.36M $56.52M
Short-Term Investments
Other Short-Term Assets $8.359M $4.438M
YoY Change 63.9% -19.31%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $50.72M $60.95M
YoY Change -58.49% -57.82%
LONG-TERM ASSETS
Property, Plant & Equipment $8.476M $12.70M
YoY Change 11.67% 56.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $142.0K $142.0K
YoY Change -29.0%
Total Long-Term Assets $8.618M $12.84M
YoY Change -20.3% 10.42%
TOTAL ASSETS
Total Short-Term Assets $50.72M $60.95M
Total Long-Term Assets $8.618M $12.84M
Total Assets $59.34M $73.80M
YoY Change -55.39% -52.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.033M $2.166M
YoY Change -18.25% -53.06%
Accrued Expenses $9.241M $4.729M
YoY Change -3.88% -53.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.283M $1.390M
YoY Change 6.92% 15.83%
Total Short-Term Liabilities $15.62M $13.14M
YoY Change -13.11% -38.81%
LONG-TERM LIABILITIES
Long-Term Debt $502.0K $869.0K
YoY Change -16.33% 24.14%
Other Long-Term Liabilities $815.0K $1.131M
YoY Change -54.95% -40.38%
Total Long-Term Liabilities $815.0K $1.131M
YoY Change -54.95% -40.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.62M $13.14M
Total Long-Term Liabilities $815.0K $1.131M
Total Liabilities $58.98M $62.90M
YoY Change -11.05% -10.22%
SHAREHOLDERS EQUITY
Retained Earnings -$275.2M -$264.1M
YoY Change 35.77% 44.4%
Common Stock $41.00K $41.00K
YoY Change 2.5% 2.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $360.0K $10.90M
YoY Change
Total Liabilities & Shareholders Equity $59.34M $73.80M
YoY Change -55.39% -52.74%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$11.16M -$18.98M
YoY Change -43.84% -22.99%
Depreciation, Depletion And Amortization $255.0K $1.693M
YoY Change -64.08% 138.45%
Cash From Operating Activities -$16.12M -$22.43M
YoY Change -13.1% -12.18%
INVESTING ACTIVITIES
Capital Expenditures $106.0K $17.00K
YoY Change -55.83% -87.41%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities -$106.0K -$17.00K
YoY Change -100.3% -99.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 73.00K $1.352M
YoY Change -102.01% -98.0%
NET CHANGE
Cash From Operating Activities -16.12M -$22.43M
Cash From Investing Activities -106.0K -$17.00K
Cash From Financing Activities 73.00K $1.352M
Net Change In Cash -16.15M -$21.09M
YoY Change -218.95% -154.62%
FREE CASH FLOW
Cash From Operating Activities -$16.12M -$22.43M
Capital Expenditures $106.0K $17.00K
Free Cash Flow -$16.23M -$22.44M
YoY Change -13.65% -12.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-24642000 usd
CY2024Q1 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
142000 usd
CY2023Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
146000 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17462000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16641000 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5445000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9574000 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
22907000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
26215000 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-19510000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-22972000 usd
CY2024Q1 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
0 usd
CY2023Q1 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
-84000 usd
CY2024Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
532000 usd
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1477000 usd
CY2024Q1 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-18978000 usd
CY2023Q1 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-24533000 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
109000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-18978000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24642000 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.93
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.93
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40938464 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40938464 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12783523 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12783523 shares
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-18978000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24642000 usd
CY2024Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 usd
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
177000 usd
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18978000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24465000 usd
CY2023Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2023Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
0 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
26532000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1057000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2282000 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-18978000 usd
CY2024Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2024Q1 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
0 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10895000 usd
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
8700885 shares
CY2022Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
107808000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-142670000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
265000 usd
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
177000 usd
CY2023Q1 carm Stock Issued During Period Values Preclosure Financing Transaction
StockIssuedDuringPeriodValuesPreclosureFinancingTransaction
30640000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
42447000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
72044000 usd
CY2023Q1 carm Reclassifications Of Temporary To Permanent Equity Shares
ReclassificationsOfTemporaryToPermanentEquityShares
-8700885 shares
CY2023Q1 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
-107808000 usd
CY2023Q1 carm Stock Issued During Period Shares Conversion Of Convertible Preferred Stock And Non Controlling Interests Upon Merger
StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger
107809000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-24642000 usd
CY2023Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2023Q1 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
0 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
86070000 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-18978000 usd
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1693000 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
705000 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1057000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
265000 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1360000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1329000 usd
CY2024Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1283000 usd
CY2024Q1 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
0 usd
CY2023Q1 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
-84000 usd
CY2024Q1 carm Accretion On Marketable Securities
AccretionOnMarketableSecurities
0 usd
CY2023Q1 carm Accretion On Marketable Securities
AccretionOnMarketableSecurities
163000 usd
CY2024Q1 carm Write Off Of Property And Equipment
WriteOffOfPropertyAndEquipment
67000 usd
CY2023Q1 carm Write Off Of Property And Equipment
WriteOffOfPropertyAndEquipment
0 usd
CY2024Q1 carm Noncash Interest Expense
NoncashInterestExpense
236000 usd
CY2023Q1 carm Noncash Interest Expense
NoncashInterestExpense
41000 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1572000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1623000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1826000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2823000 usd
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2933000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4445000 usd
CY2024Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-224000 usd
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-323000 usd
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1355000 usd
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-868000 usd
CY2024Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
50000 usd
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22425000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25534000 usd
CY2024Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0 usd
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
34460000 usd
CY2024Q1 carm Payments For Proceeds From Marketable Securities
PaymentsForProceedsFromMarketableSecurities
0 usd
CY2023Q1 carm Payments For Proceeds From Marketable Securities
PaymentsForProceedsFromMarketableSecurities
-31000000 usd
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
135000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3595000 usd
CY2024Q1 carm Cash Cash Equivalents And Restricted Cash Acquired In Reverse Recapitalization Financing Activities
CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities
0 usd
CY2023Q1 carm Cash Cash Equivalents And Restricted Cash Acquired In Reverse Recapitalization Financing Activities
CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities
37903000 usd
CY2024Q1 carm Payment Of Finance Costs Reverse Recapitalization Financing Activities
PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities
0 usd
CY2023Q1 carm Payment Of Finance Costs Reverse Recapitalization Financing Activities
PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities
1742000 usd
CY2024Q1 carm Proceeds From Issuance Of Common Stock Pre Closing Financing
ProceedsFromIssuanceOfCommonStockPreClosingFinancing
0 usd
CY2023Q1 carm Proceeds From Issuance Of Common Stock Pre Closing Financing
ProceedsFromIssuanceOfCommonStockPreClosingFinancing
30640000 usd
CY2024Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1319000 usd
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
106000 usd
CY2024Q1 carm Proceeds From Failed Sale Leaseback Transaction
ProceedsFromFailedSaleLeasebackTransaction
686000 usd
CY2023Q1 carm Proceeds From Failed Sale Leaseback Transaction
ProceedsFromFailedSaleLeasebackTransaction
1092000 usd
CY2024Q1 carm Payment Of Finance Liability Failed Sale Leaseback Transaction
PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction
303000 usd
CY2023Q1 carm Payment Of Finance Liability Failed Sale Leaseback Transaction
PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction
45000 usd
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000 usd
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2286000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1352000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
67742000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-21090000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
38613000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77605000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24194000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56515000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62807000 usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
50000 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
45000 usd
CY2024Q1 carm Noncash Or Part Noncash Acquisition Equity Assumed
NoncashOrPartNoncashAcquisitionEquityAssumed
0 usd
CY2023Q1 carm Noncash Or Part Noncash Acquisition Equity Assumed
NoncashOrPartNoncashAcquisitionEquityAssumed
122204000 usd
CY2024Q1 us-gaap Notes Reduction
NotesReduction
0 usd
CY2023Q1 us-gaap Notes Reduction
NotesReduction
42447000 usd
CY2024Q1 carm Noncash Or Part Noncash Reverse Recapitalization Costs In Accrued Expenses
NoncashOrPartNoncashReverseRecapitalizationCostsInAccruedExpenses
0 usd
CY2023Q1 carm Noncash Or Part Noncash Reverse Recapitalization Costs In Accrued Expenses
NoncashOrPartNoncashReverseRecapitalizationCostsInAccruedExpenses
4071000 usd
CY2024Q1 carm Noncash Or Part Noncash Unrealized Gain Loss On Marketable Securities
NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities
0 usd
CY2023Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
1316000 usd
CY2023Q1 carm Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash
Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash
30000 usd
CY2023Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
3499000 usd
CY2023Q1 carm Noncash Or Part Noncash Unrealized Gain Loss On Marketable Securities
NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities
177000 usd
CY2024Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4337000 usd
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2024Q1 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
2470000 usd
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0 usd
CY2024Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
59000 usd
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
49000 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-264100000 usd
CY2024Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
56500000 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited interim consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant areas that require management’s estimates include the stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and development expenses.</span></div>
CY2023Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
37873000 usd
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of credit risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</span></div>
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Marketable Securities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
44588000 usd
CY2023Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
80308000 usd
CY2023Q1 us-gaap Business Acquisition Cost Of Acquired Entity Transaction Costs
BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
8264000 usd
CY2023Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
72044000 usd
CY2024Q1 carm Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
1232000 usd
CY2023Q4 carm Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
278000 usd
CY2024Q1 us-gaap Prepaid Insurance
PrepaidInsurance
887000 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
402000 usd
CY2024Q1 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1548000 usd
CY2023Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
891000 usd
CY2024Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
771000 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1295000 usd
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4438000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2866000 usd
CY2024Q1 carm Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
3165000 usd
CY2023Q4 carm Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
3131000 usd
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
669000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1366000 usd
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
881000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3100000 usd
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
14000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
65000 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4729000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7662000 usd
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1469000 usd
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1433000 usd
CY2024Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1298000 usd
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
297000 usd
CY2024Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
236000 usd
CY2023Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
45000 usd
CY2024Q1 carm Finance Lease Cost
FinanceLeaseCost
1534000 usd
CY2023Q1 carm Finance Lease Cost
FinanceLeaseCost
342000 usd
CY2024Q1 us-gaap Variable Lease Cost
VariableLeaseCost
472000 usd
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
750000 usd
CY2024Q1 us-gaap Lease Cost
LeaseCost
3475000 usd
CY2023Q1 us-gaap Lease Cost
LeaseCost
2525000 usd
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y2M12D
CY2024Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M
CY2023Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y10M24D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.093
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.095
CY2024Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.090
CY2023Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.090
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1463000 usd
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1448000 usd
CY2024Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
236000 usd
CY2023Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
45000 usd
CY2024Q1 carm Financing Cash Used In Finance Leases
FinancingCashUsedInFinanceLeases
1319000 usd
CY2023Q1 carm Financing Cash Used In Finance Leases
FinancingCashUsedInFinanceLeases
106000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2195000 usd
CY2024Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
1153000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2628000 usd
CY2024Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
1261000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
427000 usd
CY2024Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
20000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
232000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
240000 usd
CY2024Q1 carm Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
184000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5906000 usd
CY2024Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
2434000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
673000 usd
CY2024Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
175000 usd
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
5233000 usd
CY2024Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
2259000 usd
CY2023Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3730608 shares
CY2023Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
8.21
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30600000 usd
CY2023Q1 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
5059338 shares
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
35000000 usd
CY2023Q1 carm Stock Issued During Period Shares Conversion Of Convertible Preferred Stock And Non Controlling Interests
StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests
18872711 shares
CY2023Q1 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
10374272 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6023370 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.94
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1579 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.42
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2226000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.10
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
37244 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.58
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8210547 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.43
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4241000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2737710 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.24
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3443000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
8210547 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
3.43
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y2M12D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
4241000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.72
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.64
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1057000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
265000 usd
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
13900000 usd
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M12D
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3400000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3200000 usd
CY2024Q1 carm Revenue Remaining Performance Obligation Research And Development Amount
RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount
45786000 usd
CY2024Q1 carm Revenue Remaining Performance Obligation Option Rights Amount
RevenueRemainingPerformanceObligationOptionRightsAmount
45000000 usd
CY2024Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
90786000 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
46413000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
47459000 usd
CY2024Q1 carm Contract With Customer Liability Deferral Of Revenue
ContractWithCustomerLiabilityDeferralOfRevenue
3173000 usd
CY2023Q1 carm Contract With Customer Liability Deferral Of Revenue
ContractWithCustomerLiabilityDeferralOfRevenue
2920000 usd
CY2024Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-3397000 usd
CY2023Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-3243000 usd
CY2024Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
46189000 usd
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
47136000 usd
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
carm-20240331_cal.xml Edgar Link unprocessable
0001485003-24-000009-index-headers.html Edgar Link pending
0001485003-24-000009-index.html Edgar Link pending
0001485003-24-000009.txt Edgar Link pending
0001485003-24-000009-xbrl.zip Edgar Link pending
carm-20240331.htm Edgar Link pending
carm-20240331.xsd Edgar Link pending
carm-20240331xexx311.htm Edgar Link pending
carm-20240331xexx312.htm Edgar Link pending
carm-20240331xexx321.htm Edgar Link pending
carm-20240331xexx322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
carm-20240331_def.xml Edgar Link unprocessable
carm-20240331_lab.xml Edgar Link unprocessable
carm-20240331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
carm-20240331_htm.xml Edgar Link completed
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending